Subcutaneous · GLP-1 / GIP / glucagon triple
UBT251
11 trials in this molecule. Source: ClinicalTrials.gov, as of July 6, 2026.
Trials
11
Ongoing
9
Recruiting
3
Completed
2
Sites
79
Countries
11
Endpoints
125
Composite endpoints
1
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
2
Phase 2
6
Phase 3
3
Trials by status
Not yet recruiting
6
Recruiting
3
Completed
2
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Weight & body composition
30
Glycemic / diabetes
27
Cardiometabolic biomarkers
23
MASH / liver
13
Safety / tolerability / PK
12
Other (unclassified)
10
Renal / kidney
7
Patient-reported / QoL
3
Top 20 metrics across this asset's endpoints
HbA1c, changeGlycemic
2
Fasting glucose, changeGlycemic
2
Postprandial glucoseGlycemic
1
Body weight, absolute change (kg)Weight
1
Waist circumference, changeWeight
1
HbA1c <7.0% achievementGlycemic
1
HbA1c <6.5% achievementGlycemic
1
Systolic BP, changeBiomarker
1
Diastolic BP, changeBiomarker
1
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
11 of 11
Showing 1-11 of 11 trials